Blog

Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job

At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.

Over the last two years, the pandemic has opened a window into the fascinating challenges that lie at the intersection of science and technology - where scientists and technologists can work together to solve real-world problems and improve patients’ quality of life.  This is the world that we inhabit here at BenevolentAI, where we build tech in the service of science to discover new medicines with a higher probability of clinical success. 

Despite the challenges posed by the pandemic, we’ve continued to grow our team and have virtually hired and onboarded over 100 Benevolent People across our London and New York offices and Cambridge (UK) labs. These include talented AI and machine learning scientists, software engineers, informaticians, data scientists and designers, who work alongside drug discovery scientists, chemists and pharmacologists in highly collaborative, multidisciplinary teams. As Director of Talent and Development, candidates often ask me if they need the perfect blend of science and technology backgrounds in order to be successful at Benevolent. In reality, this couldn’t be further from the truth; in a field as complex as AI-driven drug discovery, no single discipline has all the answers. 

So, what sets someone up for success at Benevolent? To quote our Lead AI Scientist, Saee Palliwal, at our Women In Tech meetup; “There is no cookie-cutter of the perfect employee”. To solve previously unsolved problems we have to have diversity of thought. Each person brings valuable insights to the table, which is what makes BenevolentAI so special: there is no such thing as a ‘stupid question’ as we look at working collaboratively with others to make a difference.  The key to being successful at Benevolent, therefore, doesn't only lie in qualifications or experience. It's also found in a person’s curiosity, their openness to having their opinion challenged and their ability to communicate technical or complex concepts in a way that someone with a completely different background can understand. Certainly, in my time at BenevolentAI, I have worked alongside some of the kindest and most intelligent people I have ever had the privilege to meet - people who are always generous with their time and willing to listen, learn and share understanding.

After all, being at Benevolent means being a part of a community that cares about creating a great place to work, where we feel challenged and inspired by the work we do and the people we work with. Recently, we were featured in Sifted in the top 10 European unicorns for Employee Satisfaction and we are phenomenally proud of our Glassdoor rating of 4.7/5, which reflects our commitment to nurturing community and culture.

Over the coming months, my team will be leading our extensive hiring efforts across drug discovery, tech and business operations - you can browse our jobs here for more information. There has never been a more exciting time to join BenevolentAI, with remarkable platform, pipeline and partnership milestones including; identifying a leading treatment for COVID-19, which is now approved by the FDA; commencing the first clinical trial for our in-house Atopic Dermatitis treatment; a successful ongoing partnership with AstraZeneca and, finally; a pro-bono research effort conducted in collaboration with the Institute of Cancer Research. The latter saw our team successfully identify a new drug combination for children with a deadly form of childhood brain cancer that has not seen survival rates improve for more than half a century. 

When you step into our London office, you’re greeted by a neon sign that reads ‘Because it Matters’. The sign is a glowing reminder of our purpose; to help patients live longer, happier lives. This common purpose drives everything we do and unites us behind a common goal, reminding us of the collective impact behind every hiring decision, every experiment and every piece of code. Every milestone and every success is something we all share, no matter where we sit in the business. We do our work ‘because it matters’, and it’s this scale and scope for lasting positive impact that makes working at BenevolentAI so rewarding - and there’s still plenty of work to be done. 

We are hiring for multiple roles across our London, Cambridge (UK) and New York locations. If you can’t find a role that fits, you can add your details to one of our Talent Pools - just pick the talent pool that fits your profile the best, and we’ll be in touch when there’s a good match with your skills and background.

Yasmina Rahiman

Director of People and Talent
More Posts

You Might Also Like

News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021